NHS Confederation

Ondine Biomedical appoints new Board of Directors

Retrieved on: 
Tuesday, December 7, 2021

Vancouver, Canada, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market.

Key Points: 
  • Vancouver, Canada, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Canadian life sciences company, Ondine Biomedical, has appointed a new Board of Directors with considerable medtech and pharma expertise following its listing on the London AIM market.
  • Carolyn Cross, Founder and CEO of Ondine, and Nicolas G. Loebel, PhD, President and Chief Technology Officer, will remain on the Board.
  • Ondine is at the forefront of development of photodisinfection-based therapies to address the large and growing need for solutions to a broad spectrum infections, including drug-resistant strains.
  • Steriwave has been deployed in Canadian hospitals for over ten years and has contributed to significant reductions in infection rates.